HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment.

AbstractGOALS:
To evaluate the impact of insurance status on tumor stage at diagnosis, treatment received, and overall survival among adults with hepatocellular carcinoma (HCC).
BACKGROUND:
Insurance status affects access to care, which impacts timely access to cancer screening for early detection and treatment.
STUDY:
Using the 2007 to 2012 Surveillance, Epidemiology, and End Results (SEER) database, we retrospectively evaluated US adults with HCC. Insurance status included Medicare/commercial insurance (MC), Medicaid (MA), and no insurance (NI). HCC tumor stage was evaluated using SEER staging system and Milan criteria. HCC treatment and survival were evaluated using multivariate logistic regression and Cox proportional hazards models.
RESULTS:
Among 32,388 HCC patients (71.2% MC, 23.9% MA, and 4.9% NI), patients with MA or NI were significantly less likely to have localized tumor stage at time of diagnosis compared with MC [NI vs. MC; odds ratio, 0.41; 95% confidence interval (CI), 0.78-0.92; P<0.001]. MA and NI patients were less likely to receive treatment, and specifically less likely to receive surgical resection or liver transplantation compared with MC patients, even after correcting for tumor stage at diagnosis (odds of surgical resection or liver transplant in NI vs. MC: odds ratio, 0.26; 95% CI, 0.21-0.33; P<0.001). NI patients (hazard ratio, 1.39; 95% CI, 1.29-1.50; P<0.001) had significantly lower survival compared with MC patients.
CONCLUSIONS:
Among US adults with HCC, MA, or NI patients had more advanced tumor stage at diagnosis, lower rates treatment, and significantly lower overall survival. Ensuring equal insurance coverage may improve access to care and mitigate some disparities in HCC outcomes.
AuthorsJennifer Wang, John Ha, Aristeo Lopez, Taft Bhuket, Benny Liu, Robert J Wong
JournalJournal of clinical gastroenterology (J Clin Gastroenterol) 2018 May/Jun Vol. 52 Issue 5 Pg. 437-443 ISSN: 1539-2031 [Electronic] United States
PMID28723861 (Publication Type: Journal Article)
Topics
  • Aged
  • Carcinoma, Hepatocellular (diagnosis, pathology, therapy)
  • Female
  • Health Services Accessibility (statistics & numerical data)
  • Healthcare Disparities (statistics & numerical data)
  • Hepatectomy (statistics & numerical data)
  • Humans
  • Insurance Coverage
  • Insurance, Health (statistics & numerical data)
  • Liver Neoplasms (diagnosis, pathology, therapy)
  • Male
  • Mass Screening (methods)
  • Medicaid (statistics & numerical data)
  • Medically Uninsured (statistics & numerical data)
  • Medicare (standards)
  • Middle Aged
  • Neoplasm Staging
  • Retrospective Studies
  • SEER Program
  • Survival Rate
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: